دورية أكاديمية
A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer
| العنوان: | A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer |
|---|---|
| المؤلفون: | Zakaria Alameddine, Muhammad Rafay Khan Niazi, Anisha Rajavel, Jai Behgal, Praneeth Reddy Keesari, Ghada Araji, Ahmad Mustafa, Chapman Wei, Abdullah Jahangir, Terenig O Terjanian |
| المصدر: | Current Oncology, Vol 30, Iss 10, Pp 9262-9275 (2023) |
| بيانات النشر: | MDPI AG, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | castrate-resistant prostate cancer, PARP inhibitors, progression-free survival, overall survival, homologous recombination repair genes, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at the forefront of the treatment of CRPC. We aim to better characterize the progression-free survival (PFS) and overall survival (OS) in metastatic CRPC patients treated with PARPis. A systemic review search was conducted using National Clinical Trial (NCT), PubMed, Embase, Scopus, and Central Cochrane Registry. The improvement in overall survival was statistically significant, favoring PARPis (hazard ratio (HR) 0.855; 95% confidence interval (CI) 0.752–0.974; p = 0.018). The improvement in progression-free survival was also statistically significant, with results favoring PARPis (HR 0.626; 95%CI 0.566–0.692; p = 0.000). In a subgroup analysis, similar results were observed where the efficacy of PARPis was evaluated in a subgroup of patients without homologous recombination repair (HRR) gene mutation, which showed improvement in PFS favoring PARPis (HR 0.747; 95%CI 0.0.637–0.877; p = 0.000). Our meta-analysis of seven RCTs showed that PARPis significantly increased PFS and OS when used with or without antihormonal agents like abiraterone or enzalutamide. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1718-7729 1198-0052 |
| Relation: | https://www.mdpi.com/1718-7729/30/10/669; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729 |
| DOI: | 10.3390/curroncol30100669 |
| URL الوصول: | https://doaj.org/article/1b8ec0743ab946eaaebd4e4567cad0a6 |
| رقم الأكسشن: | edsdoj.1b8ec0743ab946eaaebd4e4567cad0a6 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 17187729 11980052 |
|---|---|
| DOI: | 10.3390/curroncol30100669 |